TP53 and cancer: These results suggest that this oncoprotein might replace MDMX, but function similarly to the latter, to enhance MDM2's E3 ubiquitin ligase towards p53, without affecting MDM2 auto-ubiquitination and stability in cancer cells (Fig. 5a).